Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) FCF Margin (2016 - 2025)

Historic FCF Margin for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to 414.64%.

  • Editas Medicine's FCF Margin rose 905837200.0% to 414.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 389.59%, marking a year-over-year decrease of 797400.0%. This contributed to the annual value of 678.07% for FY2024, which is 5028300.0% down from last year.
  • As of Q3 2025, Editas Medicine's FCF Margin stood at 414.64%, which was up 905837200.0% from 1403.35% recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's FCF Margin peaked at 39.21% during Q4 2023, and registered a low of 115757.14% during Q3 2022.
  • Moreover, its 5-year median value for FCF Margin was 760.23% (2022), whereas its average is 12804.59%.
  • As far as peak fluctuations go, Editas Medicine's FCF Margin plummeted by -1150611800bps in 2022, and later soared by 1150881400bps in 2023.
  • Quarter analysis of 5 years shows Editas Medicine's FCF Margin stood at 300.16% in 2021, then plummeted by -119bps to 656.32% in 2022, then soared by 94bps to 39.21% in 2023, then tumbled by -327bps to 167.63% in 2024, then crashed by -147bps to 414.64% in 2025.
  • Its FCF Margin was 414.64% in Q3 2025, compared to 1403.35% in Q2 2025 and 1028.62% in Q1 2025.